Arcadia Biosciences, Inc. (RKDA) Form 10-Q — Aug 13, 2026
Arcadia Biosciences' 10-Q for the quarter ended June 30, 2026 carries substantial-doubt going-concern language: with $4.2 million of cash, management does not believe existing cash will cover requirements for the next 12 months, and without new funding or a strategic transaction the company may be forced to cut spending, liquidate assets, or pursue dissolution and bankruptcy.
Key figures
- Revenue
- 1443000
- Total Assets
- 5893000
- Cash Position
- 4178000
- Shares Outstanding
- 2409211
- Revenue period
- Q2 2026 (three months ended June 30, 2026)
- Revenue h1 2026
- 2543000
- Revenue q2 2025
- 1455000
- Afii shares held
- 2700000
- Net loss h1 2026
- 10651000
- Net loss q2 2025
- 4458000
- Total liabilities
- 5260000
- Accumulated deficit
- 291868000
- Stockholders equity
- 633000
- Revenue growth h1 yoy
- -4%
- Revenue growth q2 yoy
- -1%
- Working capital surplus
- 4093000
- Afii fair value june 30 2026
- 0
- Afii unrealized loss q2 2026
- 2781000
- January 2026 inducement loss
- 2877000
- June 2026 pipe gross proceeds
- 4000000
- June 2026 pipe valuation loss
- 5423000
- June 2026 pre funded warrants
- 3883496
- Potential dilutive securities
- 13911722
- Ieepa tariff refunds july 2026
- 169000
- Warrant and option liabilities
- 3614000
- June 2026 option exercise price
- 0.91
- Shares outstanding june 30 2026
- 2181715
- Net cash used in operations h1 2026
- 1418000
- January 2026 inducement gross proceeds
- 2100000
Price after filing
1 day: 0.0%7 days: -26.1%30 days: -24.4%
Close on the filing date to close N calendar days later (from $0.57). Historical, not a forecast.
AI analysis
Red flags10 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.